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ABSTRACT
Background: Salmonella and Shigella spp. are 2 of the most frequent and deadly enteric bacterial 
pathogens recorded worldwide. In developing countries Salmonella infections are responsible for 
many deaths annually and these mortality rates are prone to increase due to the emergence of re-
sistance to antibiotics. In this overall scenario new alternative therapeutic approaches are needed.
Methods: For the first time, we investigated the activity of 3 commercial bacteriophage cocktails 
(INTESTI, Septaphage, PYO) against a collection of contemporary Salmonella spp. (n = 30) and 
Shigella spp. (n = 20) strains isolated in Switzerland. Phage susceptibility was determined by im-
plementing the spot test.
Results: The overall susceptibility of Salmonella spp. to INTESTI and Septaphage was 87% and 
77%, respectively. With regard to Shigella spp., the overall susceptibility to INTESTI and Septa-
phage was 95% and 55%, respectively. PYO was observed to be active against only 10% of Salmo-
nella spp. but against 95% of Shigella spp.
Conclusions: Our results seem promising, especially for the INTESTI biopreparation against Sal-
monella enterica infections. Nevertheless, such speculation should be supported by further in vivo 
studies to confirm efficacy and safety of the cocktails. We also emphasize the importance of large 
in vitro screening analyses aimed to assess the activity of such biopreparations against contempo-
rary multidrug-resistant strains that are emerging worldwide.
Keywords: commercial; bacteriophages; Salmonella; Shigella; cocktails 
INTRODUCTION
Salmonella and Shigella spp. are the most frequently found and deadly enteric bacterial patho-
gens. For instance, each year 500,000 cases of diarrheal shigellosis and about 1.2 million cases of 
nontyphoidal salmonellosis with 380 deaths are recorded in the United States [1-4]. Moreover, 
in developing countries Salmonella infections are responsible for 1 million deaths annually and 
these mortality rates are likely to increase due to the emergence of resistance to commonly imple-
mented antibiotics [5, 6]. In this overall scenario, new alternative and cost-effective therapeutic 
approaches are needed. 
Bacteriophages are highly species-specific self-propagating viruses that can infect and lyse bacte-
ria. Their employment is part of the standard medical practice in countries of the former Soviet 
Union, whereas in Western nations the use of phage therapy is unfamiliar, and this has led to a 
lack of studies analyzing efficacy and possible alternatives to antibiotics [7, 8]. 
Numerous in vitro and in vivo reports exploring both lytic activity and clinical effectiveness to 
control Salmonella infections are available. However, such analyses have exclusively used mono-
phages and focused on reducing contamination of food stuffs or intestinal colonization in food 
animals [9-13]. With regard to Shigella, Mai et al tested a phage cocktail (ShigActiveTM) in a mice 
model obtaining encouraging results [14]. 
To our knowledge, data regarding the in vitro activity of bacteriophage cocktails against large col-
lections of Salmonella and Shigella spp. strains are still lacking. In this study, for the first time, we 
explored the in vitro activity of 3 commercially available bacteriophage cocktails currently imple-
mented in the country of Georgia to treat human intestinal infections.
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METHODS
The following cocktails of sterile-filtrate phage lysates of different bacterial species were tested: 
PYO Bacteriophage, INTESTI Bacteriophage (Eliava Biopreparations, Tbilisi, Georgia; concentra-
tion of 105-6 Plaque Forming Units, PFU/mL), and Septaphage (Biochimpharm, Tbilisi, Georgia; 
105 PFU/mL). PYO targets Escherichia coli, Proteus spp., Pseudomonas aeruginosa, Staphylococ-
cus spp., and Streptococcus spp., whereas INTESTI and Septaphage target over 12 gastrointestinal 
pathogens, such as Shigella, Salmonella, Proteus, Staphylococcus, Pseudomonas spp. and different 
serovars of enteropathogenic E. coli. PYO is used to treat purulent skin and surgical, oral, enteral, 
and gynecological infections, whereas INTESTI and Septaphage are implemented for intestinal 
infections [15]. Notably, INTESTI is the only molecularly well-characterized phage cocktail [16].
The collection of strains tested during the present study included contemporary Salmonella 
(n = 30) and Shigella spp. (n = 20) isolated from human infections which occurred in Switzerland. 
Species identification (ID) was routinely obtained using the matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF MS; Bruker). The ID confirmation 
and further typing were performed at the National Reference Laboratory for Enteropathogenic 
Bacteria and Listeria (Institute for Food Safety and Hygiene, Zurich, Switzerland). The antibiotic 
susceptibility profiles were obtained by disc-diffusion tests [17]. Most Salmonella spp. strains were 
pan-susceptible to tested antibiotics (ampicillin, ceftriaxone, cotrimoxazole, chloramphenicol, na-
lidixic acid, and ciprofloxacin), whereas only ceftriaxone was always active in vitro against isolates 
of Shigella spp. (Supplementary Table 1). 
Phage susceptibility was determined with the spot test with double agar overlay method [18]. 
Briefly, 100 µl of a 0.5 McFarland bacterial suspension was mixed in a brain heart infusion (BHI) 
agarose matrix (0.6%), which was then distributed to solidify on a standard BHI agar plate. Then, 
10 µl of each phage-suspension was spotted on the plate and incubated overnight. The day after, 
lysis zones were quantified [18]. Specifically, strains showing confluent lysis (complete clearing: 
++++), semi-confluent lysis (clearing throughout, but with faint hazy background: +++), opaque 
lysis (turbidity throughout the cleared zone: ++), and taches vierges (individual clear or opaque 
plaques: +) were defined as susceptible to the phage compounds tested. Strains showing no activi-
ty (no clearing: R) were defined as resistant. For all strains (n = 50) susceptibility tests were per-
formed in duplicate and on distinct days.
RESULTS AND DISCUSSION
As shown in Table 1, the overall susceptibility of Salmonella spp. to INTESTI and Septaphage 
was 86.7% (of which 23/30 were +++ or ++++) and 76.7% (none of which were +++ or ++++), 
respectively (examples in Supplementary Figure 1). With regard to Shigella spp., the overall 
susceptibility to INTESTI and Septaphage was 95% (of which 9/20 were +++ or ++++) and 55% 
(of which 3/20 were +++ or ++++), respectively. This data is promising, but we should note 
that the spot test can lead to an overestimation of the susceptibility as a consequence of the ly-
sis-from-without phenomenon [19].
We did not expect any activity for PYO against our strains because, according to the manufac-
turer, this preparation should not contain lytic phages against Salmonella spp. and Shigella spp. 
However, we were surprised to note that this cocktail was active against 10% (of which 2/30 were 
+++ or ++++) of Salmonella spp. and, more importantly, against 95% (of which 7/20 were +++ or 
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++++) of Shigella spp. This could be explained by the presence of bacteriophages unable to selec-
tively differentiate Salmonella and Shigella spp. from E. coli (all 3 being phylogenetically closely re-
lated bacterial species, especially the latter 2 [20]) that might share several common phage targets 
[21]. Moreover, taking into account the lysis-from-without phenomenon where a high multiplicity 
of infection can lead to bacterial death without infection, we are aware that by exclusively using 
the spot test, our susceptibility results might be slightly overestimated [19]. 
Table 1. Summary of the susceptibility of the Salmonella and Shigella spp. strains to the 3 com-
mercial bacteriophage cocktails
Phage Cocktails Strain groups
Results of the spot test (%) a
R + ++ +++ ++++
PYO Bacteriophage (Eliava) Overall strains (n = 50) 56.0 4.0 24.0 12.0 4.0
Salmonella spp. (n = 30) 90.0 3.3 0.0 3.3 3.3
Shigella spp. (n = 20) 5.0 5.0 55.0 30.0 5.0
INTESTI Bacteriophage (Eliava) Overall strains (n = 50) 10.0 6.0 20.0 36.0 28.0
Salmonella spp. (n = 30) 13.3 3.3 6.7 33.3 43.3
Shigella spp. (n = 20) 5.0 10.0 40.0 40.0 5.0
Septaphage (Biochimpharm) Overall strains (n = 50) 32.0 42.0 20.0 0.0 6.0
Salmonella spp. (n = 30) 23.3 53.3 23.3 0.0 0.0
Shigella spp. (n = 20) 45.0 25.0 15.0 0.0 15.0
a Strains were defined as susceptible to the bacteriophages when confluent lysis (ie, complete clearing: 
++++), semi-confluent lysis (ie, clearing throughout but with faint hazy background: +++), opaque lysis 
(ie, turbidity throughout the cleared zone: ++), taches vierges (ie, a few individual plaques: +) were record-
ed. Strains showing no activity (ie, no clearing “R”) were defined as resistant.
In conclusion, we showed the distinct spectrum and lytic activity of commercial bacteriophage 
cocktails targeting Salmonella and Shigella species. In particular, Septaphage proved to be active, 
though overall weakly, against 68% of the tested strains, whereas INTESTI exhibited a strong re-
sponse against 90% of our isolates. Therefore, our results seem promising, especially for the latter 
biopreparation against Salmonella enterica infections. Nevertheless, such speculation should be 
supported by further animal studies together with human clinical trials in order to confirm effi-
cacy and safety of cocktails. We also emphasize the importance of large in vitro screening analyses 
aimed to assess the activity of such biopreparations against contemporary multidrug-resistant 
strains emerging worldwide [2, 22, 23]. The sum of these steps, if successful, could lead to the 
maturation—also in Western countries—of an alternative approach for the treatment of bacillary 
dysenteries and salmonellosis.
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Supplementary Table 1. Characteristics of the 30 Salmonella and 20 Shigella spp. strains and 
susceptibility to 3 commercial bacteriophage cocktails
No. ID strain Species Source
Detection 
Month / 
Year
Susceptibility according 
to CLSI
Bacteriophage Susceptibility a
A
M
P
CR
O
SX
T
CH
L
N
A
L
CI
P INTESTI Septaphage PYO
1 6301.21 S. enteritidis Stool 08/16 S S S S S S ++++ + R
2 6301.22 S. enteritidis Stool 08/16 S S S S S S R + R
3 6301.23 
S. enterica 
subsp. enterica 
4,12:i
Stool 08/16 S S S S S S R + R
4 6212.52 S. enteritidis Stool 08/16 S S S S S S R + R
5 6212.46 
S. enterica 
subsp. enterica 
4,12:i
Stool 08/16 R S S S S S R + R
6 6212.47 S. enteritidis Stool 08/16 S S S S S S +++ + R
7 6211.59 
S. enterica 
subsp. enterica 
6,7:y:-
Stool 08/16 S S S S S S ++++ ++ +++
8 6211.25 S. enteritidis Stool 08/16 S S S S S S +++ + R
9 5804.66 S. paratyphi A
Blood 
culture
04/15 S S S S R I +++ + R
10 6102.20 S. typhimurium Urine 01/16 S S S S S S +++ R R
11 6103.32 S. typhimurium Stool 02/16 S S S S S S ++++ + R
12 6107.71 S. typhimurium Stool 03/16 S S S S S S ++++ ++ R
13 6007.27 S. panama Stool 11/15 S S S S S S ++++ + R
14 5804.47 S. paratyphi B Stool 04/15 S S S S S S +++ + R
15 5602.57 S. typhimurium
Blood 
culture
09/14 S S S S S S ++++ ++ R
16 5905.07 S. enteritidis Stool 08/15 S S S S S S +++ + R
17 5905.08 S. enteritidis Stool 08/15 S S S S S S ++++ ++ R
18 5602.08 S. enteritidis Stool 09/14 S S S S S S +++ ++ R
19 5512.03 S. enteritidis
Blood 
culture
08/14 S S S S S S ++++ + R
20 5603.72 S. enteritidis
Blood 
culture
09/14 S S S S S S +++ ++ R
21 4608.23 S. paratyphi A Stool 12/10 S S S S R S ++++ R R
22 4504.56 S. paratyphi A
Blood 
culture
06/10 S S S S R I ++++ R R
23 6104.03 S. paratyphi B
Blood 
culture
02/16 S S S S S S +++ R R
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24 6201.74 S. paratyphi B Stool 05/16 S S S S S S ++ + R
25 5902.41 S. typhimurium Stool 07/15 S S S S S S ++++ R R
26 5910.36 S. typhimurium Stool 09/15 S S S S S S ++++ R R
27 4108.64 S. oranienburg Stool 03/09 S S S S S S + R R
28 4310.33 S. oranienburg Stool 12/09 S S S S S S +++ + +
29 1490.92 S. choleraesuis na na - - - - - - ++++ ++ ++++
30 6302.34 S. enteritidis Stool 9/16 S S S S S S ++ + R
31 6101.40 S. sonnei Stool 01/16 S S R S S S +++ + +++
32 6105.15 S. sonnei Stool 03/16 S S R S S S +++ + +++
33 6108.73 S. sonnei Stool 04/16 - - - - - - +++ ++++ +++
34 6110.62 S. sonnei Stool 04/16 R S R S S S ++ + +++
35 6003.54 S. flexneri Stool 10/15 - - - - - - ++++ R +++
36 6004.50 S. flexneri Stool 11/15 S S R S R S ++ R ++
37 5906.08 S. flexneri Stool 08/15 S S S S S S ++ R ++
38 5509.52 S. flexneri Stool 08/14 R S R R S S R R R
39 6306.26 S. sonnei Stool 10/16 S S R S S S +++ ++++ ++
40 5703.48 S. sonnei Stool 11/14 S S R S R R + + +
41 5611.08 S. sonnei Stool 11/14 - - - - - - +++ ++++ +++
42 5605.11 S. sonnei Stool 10/14 S S R S S S ++ ++ ++
43 5402.22 S. sonnei Stool 03/14 S S R S R R ++ ++ ++
44 5312.31 S. sonnei Stool 02/14 R S S S S S ++ ++ ++
45 5203.63 S. sonnei Stool 05/13 S S R S S S ++ + ++
46 6209.65 S. flexneri Stool 08/16 - - - - - - +++ R ++
47 4907.58 S. flexneri Stool 02/12 S S R R R R +++ R ++++
48 4706.22 S. flexneri Stool 04/11 S S R S R S + R ++
49 4611.14 S. flexneri Stool 01/11 S S R S S S ++ R ++
50 4512.64 S. flexneri Stool 09/10 R S S R S S +++ R ++
Note. AMP, ampicillin; CRO, ceftriaxone; SXT, cotrimoxazole; CHL, chloramphenicol; NAL, nalidixic 
acid; CIP, ciprofloxacin; R, resistant; I, intermediate; S, susceptible; na, not available; -, not tested.
a Strains were defined as susceptible to the bacteriophages when confluent lysis (ie, complete clearing: 
++++), semi-confluent lysis (ie, clearing throughout but with faint hazy background: +++), opaque lysis 
(ie, turbidity throughout the cleared zone: ++), taches vierges (ie, a few individual plaques: +) were record-
ed. Strains showing no activity (ie, no clearing “R”) were defined as resistant.
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Supplementary Figure 1. Examples of bacteriophage susceptibility results (see Supp. Table 1) for 2 Salmo-
nella and 2 Shigella spp. strains. EI, Eliava INTESTI Bacteriophage cocktail; EP, Eliava PYO Bacteriophage 
(Eliava) cocktail; BS, Biochimpharm Septaphage Bacteriophage cocktail.
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